Historical Valuation
Can Fite Biopharma Ltd (CANF) is now in the Fair zone, suggesting that its current forward PS ratio of 243.93 is considered Fairly compared with the five-year average of -0.74. The fair price of Can Fite Biopharma Ltd (CANF) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：4.14
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Can Fite Biopharma Ltd (CANF) has a current Price-to-Book (P/B) ratio of 208.73. Compared to its 3-year average P/B ratio of 313.61 , the current P/B ratio is approximately -33.44% higher. Relative to its 5-year average P/B ratio of 190.72, the current P/B ratio is about 9.44% higher. Can Fite Biopharma Ltd (CANF) has a Forward Free Cash Flow (FCF) yield of approximately -33.91%. Compared to its 3-year average FCF yield of -47.48%, the current FCF yield is approximately -28.57% lower. Relative to its 5-year average FCF yield of -35.63% , the current FCF yield is about -4.83% lower.
P/B
Median3y
313.61
Median5y
190.72
FCF Yield
Median3y
-47.48
Median5y
-35.63
Competitors Valuation Multiple
AI Analysis for CANF
The average P/S ratio for CANF competitors is 1438.24, providing a benchmark for relative valuation. Can Fite Biopharma Ltd Corp (CANF.A) exhibits a P/S ratio of 243.93, which is -83.04% above the industry average. Given its robust revenue growth of -21.32%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for CANF
1Y
3Y
5Y
Market capitalization of CANF increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of CANF in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is CANF currently overvalued or undervalued?
Can Fite Biopharma Ltd (CANF) is now in the Fair zone, suggesting that its current forward PS ratio of 243.93 is considered Fairly compared with the five-year average of -0.74. The fair price of Can Fite Biopharma Ltd (CANF) is between to according to relative valuation methord.
What is Can Fite Biopharma Ltd (CANF) fair value?
CANF's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Can Fite Biopharma Ltd (CANF) is between to according to relative valuation methord.
How does CANF's valuation metrics compare to the industry average?
The average P/S ratio for CANF's competitors is 1438.24, providing a benchmark for relative valuation. Can Fite Biopharma Ltd Corp (CANF) exhibits a P/S ratio of 243.93, which is -83.04% above the industry average. Given its robust revenue growth of -21.32%, this premium appears unsustainable.
What is the current P/B ratio for Can Fite Biopharma Ltd (CANF) as of Jan 10 2026?
As of Jan 10 2026, Can Fite Biopharma Ltd (CANF) has a P/B ratio of 208.73. This indicates that the market values CANF at 208.73 times its book value.
What is the current FCF Yield for Can Fite Biopharma Ltd (CANF) as of Jan 10 2026?
As of Jan 10 2026, Can Fite Biopharma Ltd (CANF) has a FCF Yield of -33.91%. This means that for every dollar of Can Fite Biopharma Ltd’s market capitalization, the company generates -33.91 cents in free cash flow.
What is the current Forward P/E ratio for Can Fite Biopharma Ltd (CANF) as of Jan 10 2026?
As of Jan 10 2026, Can Fite Biopharma Ltd (CANF) has a Forward P/E ratio of -0.83. This means the market is willing to pay $-0.83 for every dollar of Can Fite Biopharma Ltd’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Can Fite Biopharma Ltd (CANF) as of Jan 10 2026?
As of Jan 10 2026, Can Fite Biopharma Ltd (CANF) has a Forward P/S ratio of 243.93. This means the market is valuing CANF at $243.93 for every dollar of expected revenue over the next 12 months.